Jump to ContentJump to Main Navigation
Show Summary Details

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board Member: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario D. C. / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.

4 Issues per year


SCImago Journal Rank (SJR) 2015: 0.447
Source Normalized Impact per Paper (SNIP) 2015: 0.524
Impact per Publication (IPP) 2015: 1.329

Online
ISSN
2363-8915
See all formats and pricing

 


Select Volume and Issue

Issues

30,00 € / $42.00 / £23.00

Get Access to Full Text

Regulatory polymorphisms in CYP2C19 affecting hepatic expression

Jonathan C. Sanford
  • Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH, USA
/ Yingying Guo
  • Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
/ Wolfgang Sadee
  • Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH, USA
/ Danxin Wang
  • Program in Pharmacogenomics, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, OH, USA
  • :
Published Online: 2013-02-14 | DOI: https://doi.org/10.1515/dmdi-2012-0038

Abstract

Background: Cytochrome P450 2C19 is responsible for the metabolism of many drugs, including the activation of clopidogrel. The allele CYP2C19*17 is associated with ultra-rapid metabolizer phenotypes by increasing gene transcription. This study tests to what extent CYP2C19*17 enhances CYP2C19 expression in human liver and whether additional regulatory variants contribute to variation in CYP2C19 expression.

Methods: CYP2C19 mRNA was measured with quantitative real-time PCR (qRT-PCR), enzyme activity as metabolic velocity with S-mephenytoin as the substrate and allelic mRNA expression ratio with SNaPshot in human livers. CYP2C19 transcribed exons and a 4kb promoter region were sequenced using IonTorrent PGM or Sanger sequencing and screened for polymorphisms associated with total hepatic CYP2C19 mRNA, enzyme activity and allelic mRNA ratios.

Results: Livers heterozygote and homozygous for CYP2C19*17 had mRNA levels 1.8-fold (p=0.028) and 2.9-fold (p=0.006), respectively, above homozygous reference allele livers. CYP2C19*17 heterozygotes were also associated with increased allelic mRNA expression (allelic ratio ~1.8-fold, SD±0.6, p<0.005), whereas CYP2C19 enzyme activity was elevated 2.3-fold, with borderline significance (p=0.06) in CYP2C19*17 carriers. One liver sample of African ancestry displayed a 2-fold allelic expression ratio, and another sample, a ~12-fold increase in metabolic velocity. Neither case was accounted for by *17, which indicates the presence of additional regulatory variants.

Conclusions: Our findings confirm *17 as a regulatory polymorphism enhancing hepatic CYP2C19 expression 2-fold with potential to compensate for the loss of function allele CYP2C19*2. Additional regulatory factors may also enhance CYP2C19 expression in African American populations.

This article offers supplementary material which is provided at the end of the article.

Keywords: allelic expression imbalance; biomarker; clopidogrel; cytochrome P450; CYP2C19; polymorphism

Corresponding author: Danxin Wang, Program in Pharmacogenomics, Department of Pharmacology, The Ohio State University, 333 West 10th Avenue, 5178 Graves Hall, Columbus, OH 43210, USA, Phone: +1 614 292-7336, Fax: +1 614 292-7232


Received: 2012-10-23

Accepted: 2013-01-03

Published Online: 2013-02-14

Published in Print: 2013-02-01


Citation Information: Drug Metabolism and Drug Interactions. Volume 28, Issue 1, Pages 23–30, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: https://doi.org/10.1515/dmdi-2012-0038, February 2013

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
K. E. Burns, W.-Y. Lo, M. P. Findlay, K. Sharples, G. Laking, and N. A. Helsby
Cancer Chemotherapy and Pharmacology, 2015
[2]
Y Shirasaka, A S Chaudhry, M McDonald, B Prasad, T Wong, J C Calamia, A Fohner, T A Thornton, N Isoherranen, J D Unadkat, A E Rettie, E G Schuetz, and K E Thummel
The Pharmacogenomics Journal, 2015
[3]
A Ortega-Vázquez, P Dorado, I Fricke-Galindo, H Jung-Cook, N Monroy-Jaramillo, I E Martínez-Juárez, I Familiar-López, E Peñas-Lledó, A LLerena, and M López-López
The Pharmacogenomics Journal, 2015
[4]
Aydan Ozkaynakci, Medine Idrizoglu Gulcebi, Deniz Ergeç, Korkut Ulucan, Mustafa Uzan, Cigdem Ozkara, Ilter Guney, and Filiz Yilmaz Onat
Neurological Sciences, 2015, Volume 36, Number 3, Page 397

Comments (0)

Please log in or register to comment.